ReviewJournal of cancer research and clinical oncology2016
Prognostic and predictive miRNA biomarkers in bladder, kidney and prostate cancer: Where do we stand in biomarker development?
Review in Journal of cancer research and clinical oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 64 citations in OpenAlex.
- Article
- Natural compounds as modulators of miRNAs: a new frontier in bladder cancer treatment.Medical oncology (Northwood, London, England) · 2025Review
- Urinary extracellular vesicle-derived miR-126-3p predicts lymph node invasion in patients with high-risk prostate cancer.Medical oncology (Northwood, London, England) · 2024Article
- Urinary extracellular vesicle-derived miR-126-3p predicts lymph node invasion in patients with high-risk prostate cancer.Research square · 2024Article
- Biomarkers for Salvage Therapy in Testicular Germ Cell Tumors.International journal of molecular sciences · 2023Review
- Integrated Microarray-Based Data Analysis of miRNA Expression Profiles: Identification of Novel Biomarkers of Cisplatin-Resistance in Testicular Germ Cell Tumours.International journal of molecular sciences · 2023Article
- Biomarkers in renal cell carcinoma and their targeted therapies: a review.Exploration of targeted anti-tumor therapy · 2023Review
- Loss of ACOX1 in clear cell renal cell carcinoma and its correlation with clinical features.Open life sciences · 2023Article
- MicroRNAs as therapeutic targets in breast cancer metastasis.Drug delivery and translational research · 2022Review
- Down-regulation of BCL2L13 renders poor prognosis in clear cell and papillary renal cell carcinoma.Cancer cell international · 2021Article
- Role of noncoding RNA in drug resistance of prostate cancer.Cell death & disease · 2021Review
- The emerging role of small non-coding RNA in renal cell carcinoma.Translational oncology · 2021Review
- Urinary MicroRNAs as Potential Markers for Non-Invasive Diagnosis of Bladder Cancer.International journal of molecular sciences · 2020Article
- Extracellular vesicles in urologic malignancies-Implementations for future cancer care.Cell proliferation · 2019Review
- miR-22 Regulates Invasion, Gene Expression and Predicts Overall Survival in Patients with Clear Cell Renal Cell Carcinoma.Kidney cancer (Clifton, Va.) · 2019Article
- MicroRNA Dysregulation and Non-Muscle-Invasive Bladder Cancer Prognosis.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2019Article
- MiRNA-545 negatively regulates the oncogenic activity of EMS1 in gastric cancer.Cancer medicine · 2018Article
- MicroRNA-195 inhibits epithelial-mesenchymal transition via downregulating CDK4 in bladder cancer.International journal of clinical and experimental pathology · 2018Article
- miR-106b-5p promotes stem cell-like properties of hepatocellular carcinoma cells by targeting PTEN via PI3K/Akt pathway.OncoTargets and therapy · 2018Article
- Dynamic plasma microRNAs are biomarkers for prognosis and early detection of recurrence in colorectal cancer.British journal of cancer · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeDefining reliable biomarkers is still a challenge in patients with urological tumors. Because miRNAs regulate diverse important cellular processes, these noncoding RNAs are putative molecular candidates. This review intends to give a critical overview about the current state of miRNAs as biomarkers in urological cancers with respect to prognostic stratification as well as for individual treatment selection.
methodsA comprehensive review of the published literature was conducted focusing at the clinical relevance of miRNAs in tissues and body fluids of prostate, bladder and kidney cancer. Using electronic database, 91 articles, published between 2009 and 2015, were selected and discussed regarding the robustness of miRNAs as valid biomarkers.
resultsA number of miRNAs have been identified with prognostic and predictive relevance in different urologic tumor types. However, the inconsistency of the published results and the lack of multivariate testing in independent cohorts do not allow an introduction into clinical decision making at present.
conclusionmiRNA-based biomarkers are a promising tool for future personalized risk stratification and response prediction in urological cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.